Every 10-Q that Corcept Therapeutics Inc. (CORT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CORT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CORT filings page.
Corcept Therapeutics generated Q1 2026 net product revenue of $164.9 million, up modestly year over year, but swung to a net loss of $31.8 million versus prior profit. The loss reflected sharply higher selling, general and administrative costs of $145.4 million and research and development spending of $66.3 million.
The company ended March 31, 2026 with cash, cash equivalents and marketable securities totaling $515.4 million, providing substantial funding for ongoing programs. In March 2026, the FDA approved Lifyorli (relacorilant) for platinum-resistant ovarian cancer, and U.S. sales began in April, adding a new oncology revenue stream alongside Korlym and its authorized generic.
Corcept Therapeutics (CORT) reported Q3 2025 results. Net product revenue was $207.6 million, up from $182.5 million a year ago, driven by a 42.5% increase in sales volume, partly offset by a 20.2% lower average price due to higher authorized‑generic mix; an August 2025 price increase partially offset the decline. Cost of sales rose to $4.6 million, including a $1.0 million inventory write‑off.
Operating expenses expanded as the company invests behind pipeline and commercialization: R&D was $68.8 million and SG&A was $124.0 million. Income from operations fell to $10.2 million (from $46.6 million). Net income was $19.7 million versus $47.2 million, with diluted EPS of $0.16 versus $0.41. Cash, cash equivalents and marketable securities totaled $524.2 million as of September 30, 2025. Year‑to‑date, the company repurchased 2.6 million shares for $172.9 million; $11.4 million remains authorized. Shares outstanding were 105,188,217 as of October 23, 2025.
Key pipeline milestones: the FDA accepted the NDA for relacorilant in hypercortisolism with a PDUFA date of December 30, 2025, and accepted the NDA for relacorilant plus nab‑paclitaxel in platinum‑resistant ovarian cancer with a PDUFA date of July 11, 2026. A Q3 tax benefit reflected newly enacted U.S. legislation allowing immediate expensing of certain R&D.